Yahoo
NasdaqCM - Delayed Quote USD

Onconetix, Inc. (ONCO)

0.7682 +0.0261 (+3.52%)
At close: 4:00:00 PM EDT
0.7051 -0.0631 (-8.21%)
After hours: 7:35:42 PM EDT
Chart Range Bar
Loading chart for ONCO
  • Previous Close 0.7421
  • Open 0.6980
  • Bid 0.5712 x 200
  • Ask 0.8970 x 200
  • Day's Range 0.6834 - 0.8300
  • 52 Week Range 0.5710 - 74.3750
  • Volume 6,395,619
  • Avg. Volume 7,465,645
  • Market Cap (intraday) 532,306
  • Beta (5Y Monthly) 3.63
  • PE Ratio (TTM) --
  • EPS (TTM) -82.8000
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

www.onconetix.com

2

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: ONCO

Trailing total returns as of 4/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ONCO
90.15%
S&P 500 (^GSPC)
4.28%

1-Year Return

ONCO
97.74%
S&P 500 (^GSPC)
29.12%

3-Year Return

ONCO
100.00%
S&P 500 (^GSPC)
71.22%

5-Year Return

ONCO
100.00%
S&P 500 (^GSPC)
70.65%

Earnings Trends: ONCO

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY23
Revenue --
Earnings --

Q4

FY22

Q1

FY23

Q2

FY23

Q3

FY23

0

Statistics: ONCO

View More

Valuation Measures

Annual
As of 3/26/2026
  • Market Cap

    514.22k

  • Enterprise Value

    -4.66M

  • Trailing P/E

    0.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.17

  • Price/Book (mrq)

    0.03

  • Enterprise Value/Revenue

    0.31

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -14.93%

  • Return on Equity (ttm)

    -115.46%

  • Revenue (ttm)

    815.37k

  • Net Income Avi to Common (ttm)

    -15.53M

  • Diluted EPS (ttm)

    -82.8000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.22M

  • Total Debt/Equity (mrq)

    0.31%

  • Levered Free Cash Flow (ttm)

    -4.49M

Compare To: ONCO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: ONCO

Fair Value

0.7682 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: